MGI Tech

BGI will have a chance to depose up to nine inventors of patents assigned to Illumina as part of a lawsuit over IP related to sequencing-by-synthesis chemistry.

A US District Court will prevent BGI from distributing and promoting certain sequencing instruments that allegedly infringe Illumina patents.

Illumina had argued that Complete Genomics' patent covering two-color sequencing-by-synthesis chemistry was obvious, but the US PTAB disagreed.

The researchers said a functional investigation of the virus' unknown transcripts and RNA modifications will elucidate its life cycle and pathogenicity.

Under the terms of the non-exclusive agreement, the companies have made Diagenode's D-Plex library preparation products available on MGI's sequencing platforms.

According to the complaint, the allegedly infringing products include all those that use nucleotides with a 3’-O-azidomethyl blocking group.

BGI is planning to offer free trials of its MGI DNBSEQ-G400 sequencing system to key opinion leaders, a development Illumina is trying to stop.

The court dismissed BGI's counterclaim against Illumina for willful infringement of its patent but allowed the claim for induced infringement to proceed.